

## REFERENCES

- Mandel J, Poch D: In the clinic: pulmonary hypertension. *Ann Intern Med* 158: 1, 2013. [PMID: 23648959]
- Galie N, Hoeper MM, Humbert M, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 30: 2493, 2009. [PMID: 19713419]
- Simonneau G, Robbins IM, Beghetti M, et al: Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 54 (1 Suppl.): S43, 2009. [PMID: 19555858]
- Shah SJ: Pulmonary hypertension. *JAMA* 308: 1366, 2012. [PMID: 23032553]
- Humbert M, Sitbon O, Chaouat A, et al: Pulmonary arterial hypertension in France: results from a national registry. *Am J Respir Crit Care Med* 173: 1023, 2006. [PMID: 16456139]
- Strange G, Playford D, Stewart S, et al: Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. *Heart* 98: 1805, 2012. [PMID: 22760869]
- Pengo V, Lensing AW, Prins MH, et al: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 350: 2257, 2004. [PMID: 15163775]
- Thenappan T, Shah SJ, Rich S, et al: Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. *Eur Respir J* 35: 1079, 2009. [PMID: 20032020]
- Nootens M, Wolfkiel CJ, Chomka EV, et al: Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. *Am J Cardiol* 75: 374, 1995. [PMID: 7856531]
- van Wolferen SA, Marcus JT, Westerhof N, et al: Right coronary artery flow impairment in patients with pulmonary hypertension. *Eur Heart J* 29: 120, 2008. [PMID: 18065750]
- Brown LM, Chen H, Halpern S, et al: Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. *Chest* 140: 19, 2011. [PMID: 21393391]
- Rich S, Dantzker DR, Ayres SM, et al: Primary pulmonary hypertension: a national prospective study. *Ann Intern Med* 107: 216, 1987. [PMID: 3605900]
- Ling Y, Johnson MK, Kiely DG, et al: Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. *Am J Respir Crit Care Med* 186: 790, 2012. [PMID: 22798320]
- McGoon M, Guterman D, Steen V, et al: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 126 (1 Suppl.): 14S, 2004. [PMID: 15249493]
- Tongers J, Schwerdtfeger B, Klein G, et al: Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. *Am Heart J* 153: 127, 2007. [PMID: 17174650]
- Rajdev A, Garan H, Biviano A: Arrhythmias in pulmonary arterial hypertension. *Progr Cardiovasc Dis* 55: 180, 2012. [PMID: 23009914]
- Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* 102: 865, 2000. [PMID: 10952954]
- Fijalkowska A, Kurzyrna M, Torbicki A, et al: Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest* 129: 1313, 2006. [PMID: 16685024]
- Andreassen AK, Wergeland R, Simonsen S, et al: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol* 98: 525, 2006. [PMID: 16893710]
- Heresi GA, Tang WH, Aytekin M, Hammel J, Hazen SL, Dweik RA: Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J* 39: 939, 2011. [PMID: 21885398]
- Benza RL, Miller DP, Gomberg-Maitland M, et al: Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation* 122: 164, 2010. [PMID: 20585012]
- Barbosa EJ Jr, Gupta NK, Torigian DA, et al: Current role of imaging in the diagnosis and management of pulmonary hypertension. *Am J Roentgenol* 198: 1320, 2012. [PMID: 22623544]
- Matthews JC, McLaughlin V: Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management. *Curr Cardiol Rev* 4: 49, 2008. [PMID: 19924277]
- Gayat E, Mebazaa A: Pulmonary hypertension in critical care. *Curr Opin Crit Care* 17: 439, 2011. [PMID: 21844798]
- Hoeper MM, Granton J: Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. *Am J Respir Crit Care Med* 184: 1114, 2011. [PMID: 21700906]
- Viitanen A, Salmenpera M, Heinonen J: Right ventricular response to hypercarbia after cardiac surgery. *Anesthesiology* 73: 393, 1990. [PMID: 2393125]
- Zamanian RT, Haddad F, Doyle RL, et al: Management strategies for patients with pulmonary hypertension in the intensive care unit. *Crit Care Med* 35: 2037, 2007. [PMID: 17855818]
- Vizza CD, Rocca GD, Roma AD, et al: Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. *Crit Care* 5: 355, 2001. [PMID: 11737925]
- Kerbaul F, Rondelet B, Motte S, et al: Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. *Crit Care Med* 32: 1035, 2004. [PMID: 15071398]
- Sztrymf B, Souza R, Bertoletti L, et al: Prognostic factors of acute right heart failure in patients with pulmonary arterial hypertension. *Eur Respir J* 35: 1286, 2009. [PMID: 19897557]
- Anderson JR, Nawarskas JJ: Pharmacotherapeutic management of pulmonary arterial hypertension. *Cardiol Rev* 18: 148, 2010. [PMID: 20395700]
- Safdar Z: Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. *Respir Med* 105: 818, 2011. [PMID: 21273054]
- Channick RN, Simonneau G, Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 358: 1119, 2001. [PMID: 11597664]
- Galie N, Rubin L, Hoeper M, et al: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Adv Pulm Hypertens* 371: 2093, 2008. [PMID: 18572079]
- Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 346: 896, 2002. [PMID: 11907289]
- Galie N, Olschewski H, Oudiz RJ, et al: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation* 117: 3010, 2008. [PMID: 18506008]
- Oudiz RJ, Galie N, Olschewski H, et al: Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *J Am Coll Cardiol* 54: 1971, 2009. [PMID: 19909879]
- Rubin LJ, Badesch DB, Fleming TR, et al: Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest* 140: 1274, 2011. [PMID: 21546436]
- Badesch DB, Hill NS, Burgess G, et al: Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol* 34: 2417, 2007. [PMID: 17985403]
- Simonneau G, Rubin LJ, Galie N, et al: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med* 149: 521, 2008. [PMID: 18936500]
- Galie N, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med* 353: 2148, 2005. [PMID: 16291984]
- Galie N, Brundage BH, Ghofrani HA, et al: Tadalafil therapy for pulmonary arterial hypertension. *Circulation* 119: 2894, 2009. [PMID: 19470885]
- Barst RJ, Oudiz RJ, Beardsworth A, et al: Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant* 30: 632, 2011. [PMID: 21256048]